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Tissue plasminogen activator (t-PA) is an extracellular serine protease that converts the proenzyme plasminogen into the broad-spectrum substrate
serine protease, plasmin. Plasmin, one of themost potent pro-angiogenic factors, is a key element in fibrinolysis, cell migration, tissue remodeling and
tumor invasion. In the present investigation, we assessed the impact of the truncated form of soluble melanotransferrin (sMTf) on plasminogen
activation by t-PA and subsequent endothelial cell detachment. Co-treatment of human endothelial microvessel cells with plasminogen, t-PA and
sMTf significantly increased plasmin formation and activity in the culture medium. Plasmin generated in the presence of sMTf also led to a 30%
reduction in fibronectin detection within cell lysates and to a 9-fold increase within the corresponding cell medium. Moreover, the presence of sMTf
increases EC detachment by 6-fold compared to cells treated only with plasminogen and t-PA. Although the addition of α2-antiplasmin completely
prevented plasmin formation and EC detachment, epigallocatechin gallate, GM6001 and a specific antibody directed against MMP-2 prevented
cellular detachment without interfering with plasminogen activation. Overall, these data suggest that the anti-angiogenic properties of sMTf may
result from local overstimulation of plasminogen activation by t-PA, thus leading to subsequent degradation of the Fn matrix and EC detachment.
© 2006 Elsevier B.V. All rights reserved.Keywords: Melanotransferrin; Plasminogen; Tissue-type plasminogen activator; Matrix metalloproteinase; Fibronectin; Endothelial cell; Detachment1. Introduction
First identified as a major antigen in human melanomas [1,2],
melanotransferrin (MTf) has been reported to be endogenously
expressed by various cell types such as intestine and renal
epithelial cells, salivary gland duct cells, liver endothelial cells
(ECs), chondrocytes and cerebral endothelium [1,3]. To date,
two variants ofMTf have been identified: one that is secreted in a
soluble form (sMTf) and the other that is associated with the cell
membrane by a glycosylphosphatidyl inositol anchor (mMTf)
[3,4]. Despite its significant homology to members of the trans-
ferrin family, MTf was shown to inefficiently transport iron into
cells [2,5]. Recently, mMTf has also been reported to act as a key⁎ Corresponding author.
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doi:10.1016/j.bbamcr.2006.03.006player in cell surface plasminogen binding and in the activation
processes involved during cell migration and invasion [6].
The angiogenic process leading to the formation of new
capillaries from pre-existing blood vessels is an important step in
embryonic development, tissue remodeling, wound healing, tumor
growth and metastasis [7–13]. Most of these processes involve a
cascade of serine proteinases and metalloproteinases (MMPs).
Plasmin, one of the most potent pro-angiogenic factors, is a key
element in fibrinolysis, cell migration, tissue remodeling and tumor
invasion [14–16]. This major serine proteinase is generated fol-
lowing cleavage of the peptidic bond between Arg560 and Val561 of
plasminogen by urokinase (u-PA) or tissue-type (t-PA) plasmino-
gen activators [17–20]. Traditionally, the role of t-PA has been
considered to be confined to fibrinolysis whereas u-PA has been
considered to be an activator of extracellular matrix (ECM) pro-
teolysis [21,22]. However, other studies have suggested a role for t-
Fig. 1. sMTf treatment triggers plasmin formation in HMEC-1. (A) Im-
munodetection of plasmin in medium of cells treated with plasminogen and
various combinations of sMTf and t-PA. (B) Plasmin activity was measured in
conditionedmedium of control cells (▪) and cells treated with plasminogen (□),
plasminogen combined with t-PA (●) or combined with t-PA and sMTf (○)
supplemented with an IgG1 control (Δ), using a chromogenic substrate as
described under Materials and methods. Values (mean ± S.E.M.) represent n = 3.
Fig. 2. Increase of plasmin formation by sMTf leads to the degradation of
fibronectin. Fibronectinwas detected byWestern blot in HMEC-1 lysates (A) and
concentrated media (B) from cells treated for 24 h with plasminogen and t-PA
with (▪) and without ( ) sMTf as well as from control, untreated cells (□).
Protein levels were quantified by densitometric analysis as described inMaterials
and methods. Values (mean ± S.E.M.) are expressed relative to control cells;
n = 3. **P b 0.005 and ***P b 0.0001.
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involved in the control of cell proliferation [24], apoptosis [21,25]
and migration [24] during the remodeling of vessel walls. In
addition, plasmin can affect the ECM organization through the
proteolysis of some components such as fibronectin [26], laminin
[27,28], proteoglycans [29] as well as fibrin, and through the
activation of MMPs [21].
MMPs are produced as latent pro-enzymes and require acti-
vation by limited proteolysis to perform their activities. MMPs
can be associated with the cell membrane (MT-MMP) or se-
creted into the extracellular environment [30]. Two particular
members of this family which are released bymost epithelial and
endothelial cells, gelatinases A and B (MMP-2 andMMP-9), are
involved in the homeostasis of the ECM [31] and seem to play an
important role in tumor invasion and metastasis [32]. Epithelial
and endothelial cells require attachment to the ECM for cell
survival [33]. Functional interactions have been described be-
tween plasminogen/plasmin and MMP systems, suggesting that
both systems cooperate in tissue remodeling [34]. Moreover,
MMPs such as pro-MMP-1 [29] and pro-MMP-3 [35] can be
activated by plasmin [21,29].
The adhesive glycoprotein fibronectin (Fn) is a central
component of the ECM involved in the regulation of adhesion-
dependent survival signaling [36]. Fn binds to cell-surface matrix
receptors through the Arg–Gly–Asp (RGD) cell binding site[37,38]. Changes in the molecular structure and composition of
the Fn matrix may provide new signals for regulating cell shape,
migration and proliferation. Modulation of the Fn matrix may
therefore be fundamental in the regulation of detachment-induced
apoptosis, also called anoïkis [37,39,40]. Although recent studies
demonstrated little Fn degradation induced by plasmin, they
established a strong link between plasmin activity and intact Fn in
the material released from endothelial cells (EC) [41].
Several studies show a growing interest in recombinant
human soluble MTf (sMTf), which is a C-terminal truncated
form of the mMTf generated by the insertion of a stop codon
after the Gly711 residue. These studies indicate that sMTf
stimulates plasminogen activation by interacting with the
single-chain zymogen pro-urokinase plasminogen activator
(pro-uPA) and with plasminogen [42], leading to the inhibition
of EC movement and tubulogenesis [43]. Considering these
findings, we investigated the potential effect of sMTf on the
activation of plasminogen in endothelial cells by the tissular-
type plasminogen activator. Our results indicate that sMTf
stimulates the formation of plasmin in the presence of t-PA and
395Y. Rolland et al. / Biochimica et Biophysica Acta 1763 (2006) 393–401exogenous glu-plasminogen, the native circulating form of the
zymogen, and affects the pericellular environment of endothe-
lial cells by degrading the ECM and activating MMPs.
2. Materials and methods
2.1. Materials
Human recombinant soluble melanotransferrin (sMTf) was obtained from
Biomarin Pharmaceutical (Novato, CA). Rabbit anti-human plasminogen IgG
(364R) and glu-plasminogen (400) were purchased from American Diagnostica
Inc. (Greenwich, CT). Human tissue plasminogen activator (t-PA) (612200) and
GM6001 (364205) were from Calbiochem (La Jolla, CA). (−)-epigallocatechin
gallate (EGCg) (E4143) and α2-antiplasmin (A8849) from human plasma were
purchased from Sigma-Aldrich (Oakville, ON). Antibodies directed against
human MMP-2 (MAB13405) and human fibronectin (F-3648) originated,
respectively, from Chemicon International Inc. (Temecula, CA) and Sigma
Immuno Chemicals (St. Louis, MO). The plasmin substrate used, VLK-pNA (S-
2251), was purchased from Chromogenix (Milan, Italy).
2.2. Cell culture
Human microvascular endothelial cells (HMEC-1) were obtained from the
Center for Disease Control and Prevention (Atlanta, GA) and were cultured at
37 °C under 5% CO2/95% air atmosphere in MCDB 131 medium (Sigma-Fig. 3. Higher levels of plasmin induce endothelial cell detachment. Human microva
sMTf and t-PA (D) and with plasminogen (E). Cell detachment was also assessed follow
(G) or both (H). After 24 h, cells were washed with PBS, photographed and analyz
plasminogen, as described under Materials and methods. Values (mean ± S.E.M.) areAldrich) containing 10 mM L-glutamine, 10 ng/mL epidermal growth factor
(EGF), 1 μg/mL hydrocortisone and 10% inactivated fetal bovine serum (FBS).2.3. Endothelial cell treatment
HMEC-1 (5 × 105 cells) were seeded onto 6-well culture plates and grown to
confluence in complete culture medium for 4 days. Cell treatment was performed
for 24 h in the presence of fresh medium supplemented with (or lacking) tissue-
type plasminogen activator (t-PA) (4 nM), glu-plasminogen (150 nM or 500 nM)
and sMTf (100 nM). The inhibitory effects of α2-antiplasmin (150 nM), EGCg
(1 μM) and GM6001 (10 μM) were also investigated. EC were also incubated
with an antibody directed against human matrix metalloproteinase-2 (MMP-2)
(20 μg/mL). Cells were then washed with a Ca2+–Mg2+-free phosphate saline
buffer (PBS) and visualized by phase-contrast microscopy. Pictures were taken at
a magnification of 100× using a digital Nikon Coolpix™ 5000 camera (Nikon
Canada, Mississauga, ON) attached to a Nikon TMS-F microscope (Nikon
Canada). Cells were then solubilized in lysis buffer (1% Triton X-100, 0,5% NP-
40, 150 mMNaCl, 1 mM ethylenediamine-tetraacetic acid (EDTA), 10 mMTris,
2% N-octylglucoside, 1 mM orthovanadate, pH 7.5). Cell media were
concentrated 10-fold using an Amicon Ultra-4 10,000 MWCO filter (Millipore
Corporation, Bedford, MA). The viability of detached EC was determined by
Trypan blue dye exclusion. Cellular detachment was analyzed by encircling the
non-cell area in four different photographs using Adobe Photoshop version 8.0
(Adobe Systems Inc., CA) and quantified by calculating the percentage coverage
of the selected area compared to non-treated cells using IPLab gel software,
Scientific Image Processing 2.0a (Signal Analytics, VA).scular endothelial cells (HMEC-1) (A) were incubated with sMTf (B), t-PA (C),
ing co-treatment with various combinations of plasminogen with sMTf (F), t-PA
ed. (I) Cell detachment was quantified in the absence (□) and presence (▪) of
expressed relative to control cells; n = 5. **P b 0.005 and ***P b 0.0001.
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Plasmin activity was analyzed by adding 10 μL of concentrated conditioned
medium to the chromogenic plasmin substrate D-Val–Leu–Arg p-Nitroanilide
(VLK-pNA) (15 μg/assay) in reaction buffer (50 nM Tris–HCl pH 7.5, 150 mM
NaCl and 50 mM CaCl2). The absorbance was monitored at 405 nm over
1 h at 37 °C with a Microplate Thermomax Autoreader (Molecular Devices,
Sunnyvale, CA).
2.5. Western blot analysis
Conditioned media and cell lysates from HMEC-1 detachment were subjected
to SDS-PAGE and separated proteins were transferred onto a polyvinylidene
difluoride membrane (PVDF) (Perkin-Elmer Life Sciences, Boston, MA).
Following transfer, immunodetection of plasminogen and fibronectin were
performed. Proteins were quantified by laser densitometry using a Chemil-
magerTM 5500 from Alpha Innotech Corporation (San Leandro, CA).Fig. 4. Modulation of plasminogen activation by various inhibitors. (A) Plasmin
formation was analyzed by Western blot in culture medium from HMEC-1
treated in the presence of plasminogen, sMTf and t-PA with or without α2-
antiplasmin, EGCg or GM6001. (B) Plasmin activity was assayed from culture
medium of cells co-treated with plasminogen, sMTf and tPA (○), to which α2-
antiplasmin (●), EGCg (▴) or GM6001 (▵) were added, using a chromogenic
substrate as described in Materials and methods. Values (mean ± S.E.M.)
represent n = 3.3. Results
3.1. sMTf stimulates plasmin formation
In light of the importance of sMTf and plasminogen interaction
[6,42], we investigated the potential effects of sMTf on the EC
plasminogen activation system. Media from cells treated with
different combinations of plasminogen, t-PA and sMTf were sub-
jected toWestern blot analysis. The activation of plasminogen by t-
PA results in the formation of plasmin, which migrates at approx-
imately Mr 50,000 during gel electrophoresis (Fig. 1A). In the
absence of treatment, ECs from human microvessels (HMEC-1)
easily convert exogenous plasminogen into plasmin, as observed
in the first lane of Fig. 1A. The addition of t-PA to the cell
medium containing plasminogen leads to complete cleavage of
the zymogen into plasmin. Moreover, the addition of sMTf to t-
PA significantly increases the formation of plasmin in conditioned
medium although the initial plasminogen concentration remained
unchanged (Fig. 1A). As previously observed [43], t-PA seems to
be a crucial player in this process since sMTf by itself, or com-
bined with plasminogen, does not lead to the formation of plasmin
(data not shown). Plasmin activity was also measured in con-
centrated media by using the conversion rate of VLK-pNA, a
chromogenic substrate of plasmin (Fig. 1B). The results indicated
that the plasmin observed by Western blot analysis possesses
normal proteolytic activity. When sMTf is combined with plas-
minogen and t-PA, the VLK-pNA hydrolysis by EC is 3-fold
higher than in conditioned medium containing only plasminogen
and t-PA, and 4-fold higher than in conditioned medium with
plasminogen alone. This difference between the levels of plasmin
activity with or without sMTf supports the increased levels of
plasmin detected in Fig. 1A. It is to note that the presence of a
non-specific IgG control did not induce an increase of plasmin
activity when added to plasminogen and t-PA, confirming that the
effect of sMTf does not results in a protein effect.
3.2. Increased degradation of fibronectin by plasmin
We further investigated whether the higher levels of plasmin
generated in the presence of sMTf would affect the structural
components of the extracellular matrix (ECM). Since vitronec-tin (Vn) and fibronectin (Fn) are two important components of
the ECM involved in cell spreading and cell attachment [44],
their degradation was studied in lysates of EC which had been
treated with different concentrations of plasminogen. While
vitronectin was not detected in quiescent nor treated HMEC-1
(data not shown), Western blot analysis showed a 30%
reduction of Fn expression in the presence of t-PA, plasminogen
and sMTf compared to incubation without sMTf (Fig. 2A). This
reduction of Fn suggests that sMTf treatment induces the
degradation of Fn by generated plasmin. Interestingly, higher
concentrations of plasminogen led to a 45% reduction in Fn
detection, while the same experiment performed with 500 nM of
sMTf did not induce further changes in Fn expression over 24 h
of treatment (data not shown). However, no degradation
fragments could be detected by Western blot since the antibody
used only recognizes the native Fn conformation. Furthermore,
Western blot analysis of medium from HMEC-1 treated with t-
PA and sMTf along with two different concentrations of
plasminogen indicated 9- and 15-fold specific increases in
native Fn (Fig. 2B).
3.3. Stimulation of EC detachment by plasmin
Previous studies indicated a strong link between plasmin
formation and EC detachment [45,46]. Since our results show that
sMTf stimulated the formation of plasmin in the presence of
Fig. 5. The MMP activation system is a key player in EC detachment. Cells were incubated in the presence of plasminogen, sMTf and t-PA with or without α2-
antiplasmin, EGCg or GM6001 (Ilomastat). HMEC-1 cells were also incubated in the presence of a specific antibody directed against human MMP-2 (control cells
were incubated with a non-specific IgG1 antibody). After 24 h of treatment, cells were washed with PBS and photographed. Cell detachment was quantified as
described in Materials and methods. Values (mean ± S.E.M.) are expressed relative to sMTf, plasminogen and t-PA co-treated cells which are designated as 100%;
n = 5. ***P b 0.0001.
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could lead to the detachment of HMEC-1. Cell adhesion was
studied in the presence of various combinations of glu-
plasminogen, t-PA and sMTf. While control cells (Fig. 3A) and
cells treated with sMTf (Fig. 3B), t-PA (Fig. 3C) or plasminogen
(Fig. 3E) did not show any morphological changes, co-treatment
of EC with t-PA and plasminogen (Fig. 3G) induced an
incomplete rounding up of the cells after 24 h. Furthermore, the
addition of sMTf (Fig. 3H) generated dramatic changes in cell
shape leading to subsequent cellular detachment. Interestingly,
co-treatment of HMEC-1 with sMTf and t-PA (Fig. 3D) or with
sMTf and plasminogen (Fig. 3F) did not alter the adhesive
properties of HMEC-1 compared to untreated cells. The EC
detachment observed eventually led to cellular death, since no
living cells were observed, using trypan blue dye exclusion,
among the detached HMEC-1 (data not shown). Quantification
of EC detachment in Fig. 3I shows that the addition of sMTf to
HMEC-1 exposed to plasminogen and t-PA increased cellular
detachment from 10-to 60-fold compared to untreated cells.3.4. Modulation of plasmin formation
In order to demonstrate that plasmin is not the only factor
responsible for EC detachment, HMEC-1 cells were treated with
various protease inhibitors known to act on different proteinase
systems. α2-antiplasmin was demonstrated to prevent plasmin
formation and to inhibit the activity of plasmin formed [47,48].
Western blot analysis shows that the addition of α2-antiplasmin
completely impeded the formation of plasmin in conditioned
medium, while neither GM6001 nor epigallocatechin gallate
(EGCg) were able to completely prevent plasmin formation (Fig.
4A), although EGCg significantly decreased plasmin formation
with a slight signal attributed to plasminogen being detected by
Western blotting (Fig. 4A). It has been reported that EGCg
inhibits both plasmin and MMP activities whereas GM6001, a
broad range MMP inhibitor, does not interfere with plasmin
formation. In agreement withWestern blot analysis, treatment of
ECs with EGCg and α2-antiplasmin decreased plasmin activity
by 50% and 100%, respectively, compared to cells exposed to
398 Y. Rolland et al. / Biochimica et Biophysica Acta 1763 (2006) 393–401t-PA, plasminogen and sMTf (Fig. 4B). Treatment of HMEC-1
with GM6001 did not induce any modulation in the activity of
plasmin, which further confirms the specificity of this inhibitor
for the MMP activation system.
3.5. Effects of various protease inhibitors on EC detachment
Since EC detachment mediated by sMTf is mainly due to the
action of plasmin, which is also known to stimulate the acti-
vation of pro-MMPs, the role of MMPs in this process was
further examined. The addition of α2-antiplasmin and EGCg
completely prevented cellular detachment of HMEC-1 while the
presence of GM6001 decreased cell detachment by 95% (Fig. 5).
These results suggest that MMPs are also involved in EC
detachment induced by sMTf.
While several cultured endothelial cells strongly express
MMP-1,-2,-3,-9 and-14 [49], HMEC-1 express high levels of
MMP-2, while no MMP-9 activity could be detected by
zymography (data not shown). An antibody directed against
the human form of MMP-2 was used to assess the potential role
of this gelatinase in EC detachment. The addition of anti-MMP-2
prevented EC detachment by 93% compared to cells treated with
a non-specific IgG1 antibody (Fig. 5).
4. Discussion
The human MTf shows strong homology with the iron trans-
porter named transferrin. Although these proteins possess similar
structure, theywere demonstrated to own distinct role, notably for
iron transport. MTf is known to be either associated to the cell
membrane or secreted in the extracellular environment. Previous
studies reported that transferrin and MTf could stimulate
angiogenesis in vitro and in vivo [50,51]. However, in these
studies, soluble transferrin and recombinantMTfwere used either
as a chemoattractant during chemotaxis and chemoinvasion as-
says, or adsorbed on gelatine sponges in chick embryo chorio-
allantoic membrane assays. The activity of a protein may depend
on numerous factors, such as three-dimensional structure. These
studies indicate that a MTf gelatine-adsorbed protein will not
exert the same properties than the equivalent soluble form. More-
over, a gelatin-adsorbed protein could be considered as non-
physiologic conditions. Human and bovine lactoferrin were
shown to inhibit tumor-induced angiogenesis [52] and to suppress
tumor growth and metastasis in the mouse and rat [53–56].
Recent work from our team demonstrated that the binding of
plasminogen tomembrane-boundmelanotransferrin could favour
its conversion into plasmin by plasminogen activator, such as u-
PA, located in the vicinity of the cell surface, thereby promoting
cell migration and invasion [6]. Our previous results reported that
sMTf treatment reduces the regeneration of free and active
urokinase plasminogen activator receptor (u-PAR) at the cell
surface, by both increasing the internalization of his scavenger
receptor the low-density lipoprotein-related protein (LRP) and
reducing its protein expression [43]. Considering the importance
of plasminogen activation at the cell surface, the modulation of
plasmin generation may take an important place in various pro-
cesses leading to angiogenesis.Activation of plasminogen, leading to plasmin formation, is
associated with extracellular matrix (ECM) degradation as it
occurs in blood clot dissolution, tissue remodeling, invasive
growth of cancer cells and angiogenesis [57–60]. Plasmin also
mediates proteolysis indirectly by the activation of MMPs,
which further degrade the ECM. Induction of plasminogen
activation leads to EC detachment [45], inhibition of cell
adhesion [20] and overstimulation of this system may result in
excessive matrix degradation and EC death [61].
Among plasminogen activators, we already demonstrated
that sMTf could affect molecular processes involving u-PA-
dependent plasminogen activation [43]. Here we demonstrate
that sMTf can also stimulate plasminogen activation by t-PA.
Our results suggest that sMTf could protect plasmin against
internalization and/or degradation, notably at the kringle do-
main level. Regulation of both the plasmin activity and the
conversion of plasminogen into plasmin are critical to avoid
inappropriate tissue damage and proteolysis of the ECM. Var-
ious mechanisms are known to be involved in the regulation of
plasmin activity. The physiological inhibitor of plasmin, α2-
antiplasmin, rapidly inactivates fluid-phase plasmin by forming
a tight complex with the proteinase [62–64]. Activated MMPs
can also digest and inactivate plasmin [65]. In addition, plasmin
is capable of autoproteolysis [66], which can be retarded by
fibrinogen and ε-aminocaproic acid [67,68]. Although recent
work from our laboratory has established that plasminogen
strongly interacts with immobilized sMTf [42], further studies
are needed to clarify the molecular mechanism by which sMTf
could facilitate plasminogen activation, delay plasmin degra-
dation and allow further activation of plasminogen and pro-
MMPs.
Under pathological conditions, plasmin could be generated
in situ at the cell surface and be responsible for inducing anoikis
by degrading pericellular adhesive glycoproteins such as fibro-
nectin, vitronectin or laminin, which participate in cell an-
chorage and survival signaling. Anoikis is a form of apoptosis
induced by detachment of adherent cells from the ECM [69].
Fibronectin is known to regulate adhesion-dependent survival
signaling [36] and to play an important role in several cellular
processes including adhesion, migration, differentiation and
growth [44]. A recent study reported that high levels of plasmin
caused a significant decrease of intact Fn in EC, but also a
concomitant increase of intact Fn in the cell medium [41]. The
reduction of Fn detection in HMEC-1 cells treated with
plasminogen, t-PA and sMTf in the present study may result
from significant cleavage by plasmin since detection of intact
Fn is increased in the corresponding cell media. Higher levels of
plasmin generated in the presence of sMTf could greatly affect
the ECM components and thus decrease cell anchorage to the
ECM. Furthermore, modulation of the Fn matrix is fundamental
in the regulation of detachment-induced apoptosis [37,39,40].
Similar results have been reported, where amyloid endostatin, a
co-factor for t-PA-mediated plasminogen activation, induced
endothelial cell-mediated plasmin formation resulting in
vitronectin degradation, cell remodeling and detachment
[70,71]. Therefore, we suggest that sMTf acts through a similar
mechanism on the Fn matrix.
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that may be implicated in the molecular events triggered by
sMTf. Members of the MMP family are crucial in ECM and
basement membrane degradation during angiogenesis. It has
already been reported that EC detachment could be plasmin-
dependent, without stimulating theMMP activation system [70].
Therefore, the authors stipulated that the plasmin generated
might not be sufficient to induce the activation of pro-MMPs. In
contrast, our results show that sMTf stimulates plasminogen
activation by t-PA in a manner sufficient to induce the activation
of pro-MMPs, considering that EGCg and GM6001 are both
capable of preventing HMEC-1 detachment.
Since MMPs seem to play an important role in the EC
detachment induced by sMTf, we sought to identify the involve-
ment of a specific proteinase. Our data from experiments done
on quiescent HMEC-1 cells show that these cells constitutively
and predominantly express MMP-2. Although the role of plas-
min in the activation of pro-MMP-2 remains unclear, several
reports have demonstrated that plasmin can activate pro-MMP-2
in the presence of MT1-MMP [72–75]. Furthermore, the
activation of MMP-2 was reported to be stimulated in human
umbilical EC (HUVEC) during apoptosis [76]. Since treatment
of HMEC-1 with a specific antibody directed against MMP-2
prevented cellular detachment, we suggest that MMP-2 activity
strongly contributes to local digestion of the ECM and, even-
tually, of the Fn matrix. Consequently, the presence of sMTf in
cell culture medium conducts to more efficient formation of
plasmin and stimulates the activity of MMP-2, leading to
increased Fn matrix degradation and finally subsequent endo-
thelial cell death following major cellular remodeling and
detachment from the ECM.
Although the activity of t-PA was conventionally associated
with fibrinolysis [21], recent work suggested a role in ECM de-
gradation during angiogenesis [23]. Furthermore, numerous studies
have revealed high levels of t-PA expression in several human
tumors [77–81], associated with good prognosis in cancer patients
[82–84]. We report here that overstimulation of the plasminogen
activation systemby sMTf leads tomajor detachment of endothelial
cells. Since t-PA expression by EC is induced by angiogenic fac-
tors, including basic fibroblast growth factor (bFGF) and vascular
endothelial growth factor (VEGF) [85], EC detachment and
subsequent cell death should play an important role in the angio-
genic process. In fact, therapeutic administration of sMTf may
result in the stimulation of plasminogen activation by t-PA pro-
duced in the tumor and interfere in EC proliferation and survival.
Taken together, overstimulation of the plasminogen activa-
tion system locally by agents such as sMTf may result in
excessive matrix degradation and endothelial cell death, thereby
preventing angiogenesis and tumor growth [71]. Although we
have previously demonstrated that sMTf reduces HMEC-1
capacity to generate plasmin from plasminogen by disturbing
the u-PAR/LRP plasminolytic system, the results shown here
indicate that, under specific conditions, such as an angiogenic
environment, sMTf may lead to EC detachment. These findings
constitute a novel pathway for interference in tumor growth and
show interesting therapeutic applications for human recombi-
nant melanotransferrin.Acknowledgements
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